Pharmacogenomics of Oncology Therapies
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (1 November 2021) | Viewed by 30249
Special Issue Editor
Special Issue Information
Dear Colleagues,
Background: Precision medicine in the form of pharmacogenomics (PGx) is an ever-increasing area of practice in the oncology care setting. Many examples exist of how genetic polymorphisms influence a drug’s effect by altering its pharmacokinetics and/or pharmacodynamics. However, for oncology therapies, which are often limited by a narrow therapeutic index and widespread inter-individual variation in response, a better understanding of how genetic factors influence drug metabolism and transport and consequent treatment outcomes is still critically needed.
Aim and Scope: The aim of this Special Issue is to outline recent trends, updates, and progress on how pharmacogenomics is improving overall cancer care on both the basic science and clinical levels.
History: The success of the Human Genome Project (HGP) ushered in a new wave of personalized approaches to medicine, including oncology care. Clinical guidelines for tailoring therapy with individual patient genotypes are established for several drug-gene pairs, such as 6-mercaptopurine/TPMT, irinotecan/UGT1A1, and 5-fluorouracil/DPYD. However, information describing the influences of genetic variability on the metabolism and transport of other cancer drugs is lacking (e.g., alkylating agents, kinase inhibitors, immunotherapies).
Cutting-edge research: Though the data are currently limited, newer pharmacogenomic studies are showing that genetic variations in non-traditional CYPs and less studied drug metabolizing enzymes significantly influence inter-individual response to anti-cancer medications.
What kind of papers we are soliciting: We are inviting the submission of original articles to this Special Issue of the Journal of Personalized Medicine that cover the whole spectrum of pharmacogenetics of oncology therapies and adjuvant drugs used in the cancer care setting from relevant case reports to full adoption in clinical settings and association studies to review articles.
Dr. Alan L. Myers
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmacogenomics
- pharmacogenetics
- oncology therapy
- cancer
- chemotherapy
- drug metabolism
- drug transport
- pharmacokinetics
- pharmacodynamics
- oncology drugs